Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia

Cardiology in the Young

Volumn 12, Issue 2, 2002, Pages 105-112

  Al Shaikh, Adnan M ^a   Abdullah, Mustafa H ^a   Barclay, Andrew ^a   Cullen Dean, Geraldine ^a   McCrindle, Brian W ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Homozygous familial hypercholesterolemia; Outcome; Plasmapheresis; Therapy

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; AORTA VALVE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HOMOZYGOSITY; HUMAN; INFANT; MALE; NEWBORN; PLASMAPHERESIS; REVIEW; SUDDEN DEATH; TREATMENT OUTCOME; AGE; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; FOLLOW UP; GENETICS; HOMOZYGOTE; HOSPITALIZATION; HYPERLIPOPROTEINEMIA TYPE 2; LOW FAT DIET; MEDICAL RECORD; METHODOLOGY; PRESCHOOL CHILD; REGISTER; RISK ASSESSMENT; SURVIVAL RATE;

ADOLESCENT; AGE FACTORS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; DIET, FAT-RESTRICTED; FEMALE; FOLLOW-UP STUDIES; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFANT; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MEDICAL RECORDS; ONTARIO; PLASMAPHERESIS; REGISTRIES; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036516789     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1047951102000240     Document Type: Review

References (27)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Goldstein JL, Hobbs HH, Brown MS (eds). The Metabolic and Molecular Bases of Inherited Diseases. New York: McGraw-Hill, 1995, pp 1981-2030.
2. Calandra S, Defesche JC, Faergeman O, Hamilton-Craig I, Hegele RA, Hopkins P. Familial Hypercholesterolemia (FH). Report of a WHO Consultation. Geneva: World Health Organization, 1998: 1-68.
3. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-466.
4. McCrindle BW. Screening and management of hyperlipidemia in children. Pediatr Annals 2000; 29: 500-508.
5. Yamamoto A, Kojima S, Harada-Shiba M, et al. Plasmapheresis for prevention and regression of coronary atherosclerosis. Ann NY Acad Sci 1995; 748: 429-439.
6. Buchwald H, Stoller DK, Campos CT, Matts JP, Varco RL. Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg 1990; 212: 318-329.
7. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311: 1658-1664.
8. Valdivielso P, Escolar JL, Cuervas-Mons V, Pulpon LA, Chaparro MA, Gonzalez-Santos P. Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia. Ann Intern Med 1988; 108: 204-206.
9. Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest 1975; 56: 1420-1430.
10. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-1154.
11. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decrease production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997; 38: 2071-2078.
12. Postiglione A, Montefusco S, Pauciullo P, Mancini M, Piliego T. Effects of atorvastatin in patients with homozygous familial hypercholesterolemia. Atherosclerosis 1999; 147: 423-424.
13. Raal FJ, Pappu AS, Illingworth DR, et al. Atherosclerosis 2000; 150: 421-428.
14. Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2000; 153: 89-98.
15. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T. Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983; 48: 157-166.
16. King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med 1980; 302: 1457-1459.
17. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J 1985; 291: 1671-1673.
18. Thiery J, Walli AK, Janning G, Seidel D. Low-density lipoprotein plasmaphaeresis with and without lovastatin in the treatment of the homozygous form of familial hypercholesterolaemia. Eur J Pediatr 1990; 149: 716-721.
19. Berger GM, Firth JC, Jacobs P, Wood L, Marais AD, Horak A. Three different schedules of low-density lipoprotein plasmapheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia. Am J Med 1990; 88: 94-100.
20. Zwiener RJ, Uauy R, Petruska ML, Huet BA. Low-density lipoprotein plasmapheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr 1995; 126: 728-735.
21. Kajinami K, Mabuchi H. Therapeutic effects of LDL plasmapheresis in the prevention of atherosclerosis. Curr Opin Lipidol 1999; 10: 401-406.
22. Sprecher DL, Schaefer EJ, Kent KM, et al. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol 1984; 54: 20-30.
23. Fredrickson DS, Levy RI. Familial hyperlipoproteinemia. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds). The Metabolic Basis of Inherited Disease, 3rd edn. New York: McGraw-Hill, 1972, p 545.
24. Rose V, Wilson G, Steiner G. Familial hypercholesterolemia: report of coronary death at age 3 in a homozygous child and prenatal diagnosis in a heterozygous sibling. J Pediatr 1982; 100: 757-759.
25. Sprecher DL, Hoeg JM, Schaefer EJ, et al. The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. Metabolism 1985; 34: 294-299.
26. Witztum JL, Simmons DM, Steinberg D, et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 1989; 79: 16-28.
27. Ose L. An update on familial hypercholesterolaemia. Ann Med 1999; 31 (Suppl 1): 13-18.